AMICUS THERAPEUTICS, INC. Forms 3, 4 and 5: Restricted Stock Units and Performance Rights
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 18 rows, 18 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2017-01-03: Reporting owner Campbell Bradley L; Form 4; Security Restricted Stock Units; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2016-01-04: Reporting owner Campbell Bradley L; Form 4; Security Restricted stock units; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2016-01-04: Reporting owner Quimi Daphne; Form 4; Security Restricted stock units; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2016-01-04: Reporting owner Peist Kenneth; Form 4; Security Restricted stock units; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2017-01-03 | Campbell Bradley L Officer (Chief Operating Officer) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −100,000 0 owned after | $0.00 | 2017-01-05 | |
| 2016-01-04 | Campbell Bradley L Officer (Chief Operating Officer) | 4 | Restricted stock units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −50,000 100,000 owned after | $0.00 | 2016-01-06 | |
| 2016-01-04 | Quimi Daphne Officer (Vice President Finance) | 4 | Restricted stock units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −25,000 0 owned after | $0.00 | 2016-01-06 | |
| 2016-01-04 | Peist Kenneth Officer (VP, Legal & IP) | 4 | Restricted stock units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −25,000 0 owned after | $0.00 | 2016-01-06 | |
| 2016-01-04 | Baird William D III Officer (Chief Financial Officer) | 4 | Restricted stock units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −50,000 0 owned after | $0.00 | 2016-01-06 | |
| 2015-12-03 | Barth Jay Officer (Chief Medical Officer) | 4 | Restricted stock units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −25,000 0 owned after | $0.00 | 2016-01-06 | |
| 2015-07-07 | Doshi Dipal Officer (SVP Strategy & Bus Dev) | 4 | Restricted stock units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | +12,500 12,500 owned after | $0.00 | 2015-07-09 | |
| 2015-05-08 | Barth Jay Officer (Chief Medical Officer) | 4 | Restricted stock units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −25,000 25,000 owned after | $0.00 | 2015-05-13 | |
| 2015-05-08 | Valenzano Ken Officer (SVP, Pharmacology & Biology) | 4 | Restricted stock units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −25,000 25,000 owned after | $0.00 | 2015-05-12 | |
| 2015-05-08 | Yu Julie Officer (VP Clinical Ops & Data Mgmt) | 4 | Restricted stock units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −25,000 25,000 owned after | $0.00 | 2015-05-12 | |
| 2015-05-08 | Quimi Daphne Officer (VP Finance and Controller) | 4 | Restricted stock units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −25,000 25,000 owned after | $0.00 | 2015-05-12 | |
| 2015-05-08 | Peist Kenneth Officer (VP, Legal & IP) | 4 | Restricted stock units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −25,000 25,000 owned after | $0.00 | 2015-05-12 | |
| 2015-05-08 | Kirk John Officer (VP, Regulatory Affairs) | 4 | Restricted stock units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −25,000 25,000 owned after | $0.00 | 2015-05-12 | |
| 2015-05-08 | Gershkowitz Jayne Officer (SVP, Chief Patient Advocate) | 4 | Restricted stock units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −25,000 25,000 owned after | $0.00 | 2015-05-12 | |
| 2015-05-08 | Dilone Enrique Officer (SVP, Technical Operations) | 4 | Restricted stock units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −25,000 25,000 owned after | $0.00 | 2015-05-12 | |
| 2015-05-08 | Castelli Jeff Officer (SVP, Program Management) | 4 | Restricted stock units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −25,000 25,000 owned after | $0.00 | 2015-05-12 | |
| 2015-05-08 | Campbell Bradley L Officer (Chief Operating Officer) | 4 | Restricted stock units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −50,000 150,000 owned after | $0.00 | 2015-05-12 | |
| 2015-05-08 | Baird William D III Officer (Chief Financial Officer) | 4 | Restricted stock units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −50,000 50,000 owned after | $0.00 | 2015-05-12 |